Efficacy of double-balloon enteroscopy-endoscopic retrograde cholangiopancreatography for hepaticojejunostomy strictures: a systematic review and meta-analysis.

Surg EndoscSep 1, 2026 (epub)
Clinical ResearchGastroenterologyOpen access

Huaqi Li, Kareem Khalaf, Yuhong Yuan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of double-balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography (DBE-ERCP) for managing hepaticojejunostomy anastomotic strictures (HJAS) in 386 patients. The pooled technical success rate was 86%, with a clinical success rate of 78% among those with technical success. Adverse events occurred in 15% of cases.

Key findings

  • Pooled technical success rate of DBE-ERCP was 86% (95% CI 79-92%).
  • Clinical success was achieved in 78% (95% CI 63-88%) of patients with technical success.
  • Adverse events occurred in 15% of cases (95% CI 5-36%).
  • Pooled incidence of recurrence was 36% (95% CI 22-52%).

Why it matters

Understanding the efficacy and safety of DBE-ERCP for HJAS is crucial for clinicians managing patients with complex surgical anatomy, as it offers a minimally invasive option with a high technical success rate.

Source

PubMed · PMID 42680928Free full text on PubMed Central

Published in Surg Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.